anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To develop a nomogram based on preoperative clinical and magnetic resonance imaging (MRI) features for the microvascular invasion (MVI) status in solitary intrahepatic mass-forming cholangiocarcinoma (sIMCC) and to evaluate whether it could predict recurrence-free survival (RFS).
METHODS: We included 115 cases who experienced MRI examinations for sIMCC with R0 resection. The preoperative clinical and MRI features were extracted. Independent predictors related to MVI+ were evaluated by stepwise multivariate logistic regression, and a nomogram was constructed. A receiver operating characteristic (ROC) curve was used to assess the predictive ability. All patients were classified into high- and low-risk groups of MVI. Then, the correlations of the nomogram with RFS in patents with sIMCC were analyzed by Kaplan-Meier method.
RESULTS: The occurrence rate of MVI+ was 38.3% (44/115). The preoperative independent predictors of MVI+ were carbohydrate antigen 19-9 > 37 U/ml, tumor size > 5 cm, and an ill-defined tumor boundary. Integrating these predictors, the nomogram exerted a favorable diagnostic performance with areas under the ROC curve of 0.767 (95% confidence interval [CI] 0.654-0.881) in the development cohort, and 0.760 (95% CI 0.591-0.929) in the validation cohort. In the RFS analysis, significant differences were observed between the high- and low-risk MVI groups (6-month RFS rates: 64.5% vs. 78.8% and 46.7% vs. 82.4% in the development and validation cohorts, respectively) (P < 0.05).
CONCLUSIONS: A nomogram based on clinical and MRI features is a potential biomarker of MVI and may be a potent method to classify the risk of recurrence in patients with sIMCC.
Chronic pain is an undesirable condition that affects a large part of the society and increases the psychological and economic burden of the population it affects. Psychological variables are known to be strong in the perception of pain and especially cause patients to avoid activity in order to reduce pain. Individuals prefer to avoid painful experiences when they are worn out in repetitive attempts to control and prevent pain, which ultimately causes pain to become more dominant and destructive, and activities that are valuable to the individual are neglected.1 At this point, accepting pain can be seen as the antithesis of avoiding painful experiences. Acceptance of pain is a strong predictor of low disability in chronic pain.2 The Chronic Pain Acceptance Questionnaire (CPAQ) represents one of the ways in which pain acceptance is functionalized and measured in the context of chronic pain. The short form of CPAQ, CPAQ-8, was developed and validated recently and shows the same factor structure, reliability and validity as the 20-factor version. Given that psychometric testing is an incremental process, further evaluation of the questionnaire is desirable, including test-retest reliability and replication of results reported by Fish et al.
Cohort 4 will include Japanese participants. Participants will receive a single dose of gepotidacin 1500 mg under fed conditions in Period 1 (Treatment H), then a single dose of gepotidacin 1500 mg under fasted conditions in Period 2 (Treatment I), followed by two doses of gepotidacin up to 3000 mg (given 12 hours apart) under fed conditions in Period 3 (Treatment J). There will be a washout of at least 3 days between each treatment, and a follow-up visit 5 to 7 days after the last dose of gepotidacin.
Subjects will be recruited according to our inclusion/exclusion criteria. The investigators employ a multifaceted approach to recruitment, including flyers, community newspaper ads, internet ad postings, and direct recruitment from the Internal Medicine Clinics of Froedtert Memorial Lutheran Hospital/Medical College of Wisconsin which saw approximately 50,000 unique outpatient visits over last year. The electronic health record is leveraged to identify potential subjects by HIPAA guidelines and Medical College of Wisconsin policies. Potential subjects will undergo phenotyping that includes a detailed medical history, anthropomorphic measurements, blood pressure and heart rate measurements, and a blood draw for measurements that include fasting lipids, glucose, and glycosylated hemoglobin, creatinine, and liver function tests. Healthy, non-DM subjects who pass the screening as per the inclusion/exclusion criteria in Table 2 will be enrolled in the study protocol.

Following an overnight fast (12 hours), subjects will come in the morning to our Adult Translational Research Unit (A-TRU) which is part of the Clinical Translational Research Initiative of Southeast Wisconsin (8UL1TR000055). An antecubital intravenous line will be placed to facilitate blood glucose sampling during the hyperglycemic challenge. An antecubital intravenous catheter will be placed to facilitate obtaining endothelial cells from the vein by J-wire biopsy for of mitochondrial testing. The principal investigator has published experience with the J-wire endothelial cell biopsy technique, and the technique has been extensively validated technique. An initial venous glucose sample will be taken from the antecubital vein and an initial J-wire biopsy of the radial artery endothelium will be performed through the radial arterial line. Subjects will then be asked to drink a standardized 75 g glucose drink created by the A-TRU nutritionist- a standard oral glucose challenge as used clinically. Blood glucose samples will be taken hourly after that until 4 hours post drink ingestion. At one and 4 hours post-ingestion, J-wire endothelial biopsies of the radial artery will be repeated. Four separate J wires will be passed into the radial artery for each measurement time point (0,1, and 4 hours).

In non-diabetic subjects, the 75 g oral challenge induces a peak increase in systemic glucose at 1-hour post-administration at which time endothelial dysfunction is concomitantly detectable. Endothelial cells will be obtained via J-wire capture technique. A portion of the endothelial cells isolated from the J-wires will be used to measure mitochondrial network complexity prior hyperglycemic challenge, 1-hour post challenge, and 4 hours post challenge. The investigators will visualize the mitochondrial networks in these cells using our previously reported and validated immunofluorescence method using cytochrome c antibodies to tag the mitochondria. Network fragmentation (high number=greater fragmentation and fission) will be quantified by network fragmentation count calculated with ImageJ (NIH, Bethesda) using a validated protocol.
Oral transmucosal fentanyl citrate contains fentanyl, a substance with a high potential for abuse similar to other opioids including hydrocodone, hydromorphone, methadone, morphine oxycodone, oxymorphone, and tapentadol. Oral transmucosal fentanyl citrate can be abused and is subject to misuse, addiction, and criminal diversion [see Warnings and Precautions (5.6)].

All patients treated with opioids require careful monitoring for signs of abuse and addiction, since use of opioid analgesic products carries the risk of addiction even under appropriate medical use.

Prescription drug abuse is the intentional non-therapeutic use of a prescription drug, even once, for its rewarding psychological or physiological effects.

Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use and includes: a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, increased tolerance, and sometimes a physical withdrawal.

“Drug-seeking” behavior is very common in persons with substance use disorders. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing, or referral, repeated “loss” of prescriptions, tampering with prescriptions, and reluctance to provide prior medical records or contact information for other treating healthcare provider(s). “Doctor shopping” (visiting multiple prescribers to obtain additional prescriptions) is common among drug abusers and people suffering from untreated addiction. Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with poor pain control.

Abuse and addiction are separate and distinct from physical dependence and tolerance. Healthcare providers should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. In addition, abuse of opioids can occur in the absence of true addiction. 

Oral transmucosal fentanyl citrate, like other opioids, can be diverted for non-medical use into illicit channels of distribution. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised.

Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.

Risks Specific to the Abuse of Oral Transmucosal Fentanyl Citrate   
Oral transmucosal fentanyl citrate is for oral transmucosal use only. Abuse of oral transmucosal fentanyl citrate poses a risk of overdose and death. The risk is increased with concurrent abuse of oral transmucosal fentanyl citrate with alcohol and other central nervous system depressants.
PURPOSE:To provide a stable elastin hydrolysate aqueous solution causing no cloudiness and precipitate by compounding propylene glycol or 1,3-butylene glycol with an elastin hydrolysate aqueous solution. CONSTITUTION:10-30wt.% of 1,3-butylene glycol and/or propylene glycol are compounded with the aqueous solution of an elastin hydrolysate having a mol.wt. of >=200,000. The addition of the prepared solution to cosmetics or external agents on the preparations thereof can prevent the cloudiness and precipitation of the elastin and provide products having good water retainability, moisture retention and feeling. The elastin hydrolysate having a mol.wt. of >=200,000 is prepared by subjecting the elastin existing in the ligamentum nuchae, etc., of a mammalian to a enzymatic hydrolysis using a protease such as an esterase or pepsin or to an acidic hydrolysis.
As with all therapeutic proteins, there is a potential for immunogenicity. 

The detection of antibody formation is highly dependent on the sensitivity and the specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other trastuzumab products may be misleading.

Among 903 women with metastatic breast cancer, human anti-human antibody (HAHA) to trastuzumab was detected in one patient using an enzyme-linked immunosorbent assay (ELISA). This patient did not experience an allergic reaction. Samples for assessment of HAHA were not collected in studies of adjuvant breast cancer.
The present invention relates to methods and compositions for modulating CD47-mediated PMN transmigration across a cell layer. Monoclonal antibodies and functionally active antibody fragments which specifically bind to the CD47 antigen are provided. These antibodies and fragments are useful in screening assays to identify pharmaceutical lead compounds which likewise are capable of modulating CD47-mediated PMN transmigration across a cell layer. Methods and pharmaceutical compositions for modifying the immune response of a subject also are provided. The antibodies and fragments are based upon, or derived from, the C5/D5 antibody having ATCC Accession No. HB-12021.
The administration of ROXICET (Oxycodone and Acetaminophen) or other opioids may obscure the diagnosis or clinical course in patients with acute abdominal conditions.

ROXICET should be given with caution to patients with CNS depression, elderly or debilitated patients, patients with severe impairment of hepatic, pulmonary, or renal function, hypothyroidism, Addison's disease, prostatic hypertrophy, urethral stricture, acute alcoholism, delirium tremens, kyphoscoliosis with respiratory depression, myxedema, and toxic psychosis.

ROXICET may obscure the diagnosis or clinical course in patients with acute abdominal conditions. Oxycodone may aggravate convulsions in patients with convulsive disorders, and all opioids may induce or aggravate seizures in some clinical settings.

Following administration of ROXICET, anaphylactic reactions have been reported in patients with a known hypersensitivity to codeine, a compound with a structure similar to morphine and oxycodone. The frequency of this possible cross-sensitivity is unknown.
Male and female individuals aged 18 to 23 years will be evaluated. The Research Diagnostic Criteria for Temporomandibular Disorders will be applied for the determination of the presence or absence of temporomandibular disorder. Each group (with and without temporomandibular disorder) will then be randomly allocated into a control group and experimental group submitted to pre-fatigue low-level laser therapy. Before and after the induction of fatigue, all volunteers will be evaluated with regard to the range of mandibular movement, bite force, sensitivity to palpation of the muscles evaluated and muscle fatigue. Low-level laser therapy will be administered to the masseter and anterior temporal muscles prior to the induction of fatigue, which will be induced with the use of chewing gum. The data will be submitted to descriptive statistical analysis. The chi-square test and Fisher's exact test will be used to establish the associations of the categorical variables. Pearson correlation coefficients will be calculated for the analysis of the correlation of the continuous variables.
1. Technical result Creation of novel, more active and less toxic agents of this class.         2. Essence N,N-dimethyl-2-[5-(2-oxo-1,3-oxazolidin-4-yl- methyl)-1H-indol-3-yl)ethylamine is deleted. Indole derivatives of formula I are useful in prophylaxis of clinical states for which administration of "5-HT1- like receptor agonist is recommended. Also described are method of preparation thereof, drug based on indole derivatives of formula I and method of preparing drug; EFFECT: improved properties of the drug and more efficient preparation method thereof 3. Field of Application Medicine, pharmacology.
A novel composition for treating symptoms such as symptoms of a common cold, a sore throat, congestion, laryngitis, mucous membrane inflammation and sialorrhea is disclosed. The composition includes ingredients to obtainable from turmeric extract, ginger root powder, and horseradish root powder. This composition can be orally administered a patient. The composition may further include ingredients obtainable from slippery elm bark powder and green tea. This composition may further include a pharmaceutically acceptable carrier for oral administration.  
     A method of administering this composition orally to a patient to treat symptoms of a common cold, a sore throat, congestion, laryngitis, mucositis, sialorrhea and mucous membrane inflammation is also disclosed. To treat these symptoms, the composition is administered to a patient suffering one to fifteen times daily, as needed. To achieve the best effect, the composition should be held in the mouth of a patient for 5 to 60 minutes.
This is a 28-week, randomized (the study medication is assigned by chance), open-label (all people know the identity of the intervention), active-controlled (patients are assigned to either a recognized effective treatment or the study medication) comparative study. All patients will enter a run-in period to receive a stable therapeutic dose of oral risperidone immediate-release for at least 4 weeks. After the 4-week run-in period, patients will be randomly assigned to either remain on oral risperidone immediate-release (IR) or to receive a therapeutic dose of oral paliperidone extended-release (ER) and patients will be prospectively followed for a 24-week treatment phase. The treatment phase is composed of a 4-week flexible dose period followed by a 20-week stable dose period. During the 4-week flexible dose period, the dose of paliperidone ER or risperidone IR may be increased or decreased for each patient if clinically indicated (eg, significant side effects emerge or there is evidence of a lack of efficacy). At the end of 4-week flexible dose period, the final dose should be maintained for the 20-week fixed-dose period. Efficacy and safety will be assessed at baseline (Week 0) and Weeks 4, 12, and 24.
PURPOSE:To provide a dermatic drug for external application, free from hormone-like action, giving mild action to the skin, and having excellent remedying effect to pimples, by using oxendolone known as a remedy for prostatomegamy as an active component. CONSTITUTION:The objective agent for the remedy of pimples is obtained by using oxendolone (16beta-ethyl-17beta-hydroxy-4-estern-3-one) as an active component. The amount of oxendolone is about 0.001-2wt%. It is administered in the form suitable for the application to the skin, e.g. cream, ointment, lotion, etc. The agent may be compounded with an antibacterial agent such as hexachlorophene, vitamin A acid, zinc, keratolytic agent, etc. within a range to keep the effect of the present invention.
Data will be collected in 12 countries (500 children per site) from five major regions of the world (Eurasia \& Africa, Europe, Latin America, North America, and the Pacific). Cross-sectional evaluations will be undertaken in each country. The physical characteristics of the children will be directly measured in order to classify their body weight and adiposity status, and physical activity and dietary patterns will be measured with the most objective techniques currently available. A concise set of environmental measures that are feasible, valid and meaningful across the international settings included in this research will also be employed. The results of this study will provide a robust examination of the correlates of obesity and weight gain in children, focusing on both sides of the energy balance equation. The results will also provide important new information that will inform the development of lifestyle interventions to address childhood obesity that can be culturally adapted for implementation around the world.
FIELD: immunology, biotechnology, peptides, pharmacy. SUBSTANCE: peptide shows the following amino acid sequence: ELDKWAS, LELDKWAS, ELDNWAS, ELNKWAS, LELDNWAS or LELNKWAS and promotes to the formation of antibodies. Peptide can be bound with a carrier as virus or viral protein. Peptide bound with a carrier is prepared by recombinant method. Antibody with HIV-1-neutralizing activity and secreted by mucosa envelope surface is prepared by immunization of human or animal. Invention ensures to develop a pharmaceutical agent promoting to the formation of antibodies to strains HIV-1 and/or clinical isolates. Invention can be used for preparing neutralizing antibodies raised to different strains and clinical isolates of HIV-1. EFFECT: improved method of peptide and antibody production. 17 cl, 9 dwg, 1 tbl, 7 ex
Observational studies and clinical trials have demonstrated that clinicians fail to intensify therapy in hypertensive management despite patients not meeting goal. For this reason, patient centered tools can help facilitate meeting goals with the provider. Web-based communication combined with provider care management successfully lowered blood pressure to \<140/90 mm Hg in prior studies of patients with hypertension. Emerging technology now provides the ability for patients to upload self-measured home blood pressure information into their own medical record which may eliminate the need for additional health personnel. This study will investigate the feasibility of health informatics to facilitate better compliance and safety for both provider and patient for hypertension management. The home blood pressure readings along with patient reported symptoms will be recorded using the MyChart, a web-based tool available to all patients receiving care at Loyola University Medical Center. MyChart can be accessed with a hand-held device or home computer. After enrollment, patients will receive a notice every two weeks via MyChart to upload home blood pressure values and patient reported symptoms. This information entered into MyChart by patients will be placed into the electronic health record in a home vital signs flow sheet, which will be separate from the flow sheet of vital signs measured in the clinic. Physicians will receive an alert message when patients upload the blood pressure data. The alert message will provide physicians with the average blood pressure value over the two weeks and will provide simple guidance on whether actions, such as titrating existing medication should be taken (based on whether BP is ≥ 140/90 mmHg). Patients will also be able to track their own home blood pressure values using the MyChart application. As a first step, we are first examining the feasibility of this web-based application and determining the perceptions of both patients and physicians.